Rasagiline interferes with neurodegeneration in the Prph2/rds mouse.
Eigeldinger-Berthou S, Meier C, Zulliger R, Lecaudé S, Enzmann V, Sarra GM.
Retina · research support, non-u.s. gov't; journal article · DOI 10.1097/iae.0b013e31821e2070 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för rasagiline. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
15 träffarType A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase.
Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M.
J Neural Transm (Vienna) · research support, non-u.s. gov't; journal article · DOI 10.1007/s00702-011-0730-6Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
Wilson RE, Seeberger LC, Silver D, Griffith A, Conner JB, Salzman PM, LEGATO Investigators.
Neurologist · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1097/nrl.0b013e31822f6872Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease.
Chitnis S, Jaffery M, Dewey RB.
Int J Neurosci · comparative study; clinical trial; journal article; research support, n.i.h., extramural · DOI 10.3109/00207454.2011.617016Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline.
Jenner P, Langston JW.
Mov Disord · research support, non-u.s. gov't; systematic review; journal article · DOI 10.1002/mds.23926Effect of rasagiline on the molecular composition of the excitatory postsynaptic density.
Gardoni F, Zianni E, Eramo A, Canonico PL, Di Luca M.
Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2011.09.028Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Stocchi F, Rabey JM.
Eur J Neurol · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1111/j.1468-1331.2011.03512.xEfficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E, Stern MB.
Eur J Neurol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1111/j.1468-1331.2011.03484.xDetermining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.
Silver DE, Buck PO.
Int J Neurosci · review; journal article · DOI 10.3109/00207454.2011.582240Rasagiline-induced delay of retinal ganglion cell death in experimental glaucoma in rats.
Levkovitch-Verbin H, Vander S, Melamed S.
J Glaucoma · journal article · DOI 10.1097/ijg.0b013e3181e3d101The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
Chen JJ, Wilkinson JR.
J Clin Pharmacol · review; journal article · DOI 10.1177/0091270011406279The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, Gunal DI, Yener GG, Cakmur R, Sahin HA, Emre M.
Mov Disord · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1002/mds.23738A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.
Lancet Neurol · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1474-4422(11)70073-4Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
Weinreb O, Amit T, Riederer P, Youdim MB, Mandel SA.
Int Rev Neurobiol · review; journal article · DOI 10.1016/b978-0-12-386467-3.00007-8Rasagiline in Parkinson's disease.
Chahine LM, Stern MB.
Int Rev Neurobiol · review; journal article · DOI 10.1016/b978-0-12-386467-3.00008-x